205 related articles for article (PubMed ID: 30567877)
1. Hepatic Enzymes Relevant to the Disposition of (-)-∆
Patilea-Vrana GI; Anoshchenko O; Unadkat JD
Drug Metab Dispos; 2019 Mar; 47(3):249-256. PubMed ID: 30567877
[TBL] [Abstract][Full Text] [Related]
2. Quantifying Hepatic Enzyme Kinetics of (-)-∆
Patilea-Vrana GI; Unadkat JD
Drug Metab Dispos; 2019 Jul; 47(7):743-752. PubMed ID: 31048453
[TBL] [Abstract][Full Text] [Related]
3. Characterizing and Quantifying Extrahepatic Metabolism of (-)-Δ
Kumar AR; Patilea-Vrana GI; Anoshchenko O; Unadkat JD
Drug Metab Dispos; 2022 Jun; 50(6):734-740. PubMed ID: 35370140
[TBL] [Abstract][Full Text] [Related]
4. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids.
Mazur A; Lichti CF; Prather PL; Zielinska AK; Bratton SM; Gallus-Zawada A; Finel M; Miller GP; Radomińska-Pandya A; Moran JH
Drug Metab Dispos; 2009 Jul; 37(7):1496-504. PubMed ID: 19339377
[TBL] [Abstract][Full Text] [Related]
5. Development and Verification of a Linked
Patilea-Vrana GI; Unadkat JD
Drug Metab Dispos; 2021 Jul; 49(7):509-520. PubMed ID: 33952608
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
Bansal S; Paine MF; Unadkat JD
Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300
[TBL] [Abstract][Full Text] [Related]
8. CYP3A4 is a major isoform responsible for oxidation of 7-hydroxy-Delta(8)-tetrahydrocannabinol to 7-oxo-delta(8)-tetrahydrocannabinol in human liver microsomes.
Matsunaga T; Kishi N; Higuchi S; Watanabe K; Ohshima T; Yamamoto I
Drug Metab Dispos; 2000 Nov; 28(11):1291-6. PubMed ID: 11038155
[TBL] [Abstract][Full Text] [Related]
9. The impact of pregnancy and associated hormones on the pharmacokinetics of Δ
Authement AK; Isoherranen N
Expert Opin Drug Metab Toxicol; 2024; 20(1-2):73-93. PubMed ID: 38258511
[TBL] [Abstract][Full Text] [Related]
10. Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers.
Wolowich WR; Greif R; Kleine-Brueggeney M; Bernhard W; Theiler L
Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):691-711. PubMed ID: 31114948
[TBL] [Abstract][Full Text] [Related]
11. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
Bansal S; Maharao N; Paine MF; Unadkat JD
Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
[TBL] [Abstract][Full Text] [Related]
12. Relating Observed Psychoactive Effects to the Plasma Concentrations of Delta-9-Tetrahydrocannabinol and Its Active Metabolite: An Effect-Compartment Modeling Approach.
Awasthi R; An G; Donovan MD; Boles Ponto LL
J Pharm Sci; 2018 Feb; 107(2):745-755. PubMed ID: 28942005
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes.
Lapham K; Callegari E; Cianfrogna J; Lin J; Niosi M; Orozco CC; Sharma R; Goosen TC
Drug Metab Dispos; 2020 Dec; 48(12):1350-1363. PubMed ID: 33020067
[TBL] [Abstract][Full Text] [Related]
14. Monkey hepatic microsomal alcohol oxygenase: purification and characterization of a cytochrome P450 enzyme catalyzing the stereoselective oxidation of 7alpha- and 7beta-hydroxy-delta8-tetrahydrocannabinol to 7-oxo-delta8-tetrahydrocannabinol.
Matsunaga T; Iwawaki Y; Komura A; Watanabe K; Kageyama T; Yamamoto I
Biol Pharm Bull; 2002 Jan; 25(1):42-7. PubMed ID: 11824554
[TBL] [Abstract][Full Text] [Related]
15. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.
Zhang D; Wang L; Chandrasena G; Ma L; Zhu M; Zhang H; Davis CD; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):139-49. PubMed ID: 17062778
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites.
Nasrin S; Watson CJW; Bardhi K; Fort G; Chen G; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1081-1089. PubMed ID: 34493601
[TBL] [Abstract][Full Text] [Related]
17. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
Jiang R; Yamaori S; Takeda S; Yamamoto I; Watanabe K
Life Sci; 2011 Aug; 89(5-6):165-70. PubMed ID: 21704641
[TBL] [Abstract][Full Text] [Related]
18. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
Qian Y; Gurley BJ; Markowitz JS
J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
[TBL] [Abstract][Full Text] [Related]
19. AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5'-Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
Kim JH; Kwon SS; Kong TY; Cheong JC; Kim HS; In MK; Lee HS
Molecules; 2017 Mar; 22(3):. PubMed ID: 28287454
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
Kong TY; Kwon SS; Cheong JC; Kim HS; Kim JY; Lee HS
Molecules; 2018 Apr; 23(4):. PubMed ID: 29659506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
